Taysha Gene Therapies, Inc. ( TSHA) - Key Metrics
TSHA Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.13 | -$0.11 | -$0.11 |
| 2026Q1 | $0 | -$0.12 | -$0.11 | -$0.12 |
| 2025Q4 | $0.02 | -$0.09 | -$0.08 | -$0.08 |
| 2025Q3 | $0 | -$0.09 | -$0.07 | -$0.07 |
| 2025Q2 | $0.01 | -$0.09 | -$0.07 | -$0.07 |
TSHA Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -13.10 |
| 2026Q1 | 0% | -9.31 |
| 2025Q4 | 0% | -17.19 |
| 2025Q3 | 0% | -8.83 |
| 2025Q2 | 0% | -6.40 |
TSHA
Price: $3.73
52 week price:
Earnings Per Share: -0.41 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.1 million
Market Capitalization: 1.4 billion